Benzinga | Jan 10, 2022 10:01AM EST

Biogen Executive Says Rolling Submission For Accelerated Approval Of Second Alzheimer's Drug Lecanemab Ongoing, Expected To Be Completed In H1 2022

-JP Morgan Conference